Risk of severe COVID-19 in unvaccinated patients during the period from wild-type to Omicron variant: real-world evidence from Japan

被引:0
|
作者
Tomioka, Kimiko [1 ,2 ]
Uno, Kenji [2 ,3 ]
Yamada, Masahiro [2 ]
机构
[1] Nara Med Univ, Nara Prefectural Hlth Res Ctr, Nara, Japan
[2] Chuwa Publ Hlth Ctr Nara Prefectural Govt, Nara, Japan
[3] Minami Nara Gen Med Ctr, Dept Infect Dis, Nara, Japan
关键词
COVID-19; SARS-CoV-2; Severe outcomes; Wild-type; Omicron; Community-based study; Japan; SARS-COV-2; INFECTION;
D O I
10.1265/ehpm.23-00274
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Many studies have reported that the Omicron variant is less pathogenic than the Delta variant and the wild-type. Epidemiological evidence regarding the risk of severe COVID-19 from the wild-type to the Omicron variant has been lacking. Methods Study participants were COVID-19 patients aged 18 and older without previous COVID-19 infection who were notified to the Nara Prefecture Chuwa Public Health Center from January 2020 to March 2023, during the periods from the wild-type to the Omicron variant. The outcome variable was severe COVID-19 (i.e., ICU admission or COVID-19-related death). The explanatory variable was SARS-CoV-2 variant type or the number of COVID-19 vaccinations. Covariates included gender, age, risk factors for aggravation, and the number of general hospital beds per population. The generalized estimating equations of negative binomial regression models were used to estimate the adjusted incidence proportion (AIP) with 95% confidence interval (CI) for severe COVID-19. Results Among 77,044 patients included in the analysis, 14,556 (18.9%) were unvaccinated and 520 (0.7%) developed severe COVID-19. Among unvaccinated patients, the risk of severe COVID-19 increased in the Alpha/Delta variants and decreased in the Omicron variant compared to the wild-type (AIP [95% CI] was 1.55 [1.06-2.27] in Alpha/Delta and 0.25 [0.15-0.40] in Omicron), but differed by age. Especially in patients aged >= 80, there was no significant difference in the risk of severe COVID-19 between the wild-type and the Omicron variant (AIP [95% CI] = 0.59 [0.27-1.29]). Regarding the preventive effect of vaccines, among all study participants, the number of vaccinations was significantly associated with the prevention of severe COVID-19, regardless of variant type. After stratified analyses by age, patients aged >= 80 remained a significant association for all variant types. On the other hand, the number of vaccinations had no association in Omicron BA.5 of patients aged 18-64. Conclusions Patients aged >= 80 had less reduction in risk of severe COVID-19 during the Omicron variant period, and a greater preventive effect of vaccines against severe COVID-19, compared to younger people. Our findings suggest that booster vaccination is effective and necessary for older people, especially aged >= 80.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Estimation of Real-World Vaccination Effectiveness of mRNA COVID-19 Vaccines against Delta and Omicron Variants in Japan
    Kodera, Sachiko
    Rashed, Essam A.
    Hirata, Akimasa
    [J]. VACCINES, 2022, 10 (03)
  • [22] A Real-World Evidence Framework for Optimizing Dosing in All Patients with COVID-19
    Peck, Richard W.
    Weiner, Daniel
    Cook, Jack
    Robert Powell, J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (05) : 921 - 923
  • [23] Effect of Hypertension Comorbidity on Clinical Characteristics of COVID-19 Patients Infected by the Wild-Type, the Delta or Omicron Variant SARS-CoV-2
    Zhang, Jinhui
    Zhang, Jianguo
    Tao, Zhimin
    [J]. REVIEWS IN CARDIOVASCULAR MEDICINE, 2022, 23 (12)
  • [24] Risk factors and drug efficacy for severe illness in hemodialysis patients infected with the Omicron variant of COVID-19
    Wu, Yan
    He, Lingling
    Guo, Yongping
    Wang, Niansong
    [J]. KIDNEY & BLOOD PRESSURE RESEARCH, 2023, 48 (01): : 642 - 651
  • [25] COVID-19 omicron variants demonstrated different virulence in infected patients with cancer: The real-world evidence from the National COVID Cohort Collaborative (N3C).
    Song, Qianqian
    Bates, Benjamin
    Hsu, Fang-Chi
    Liu, Feifan
    Madhira, Vithal
    Mitra, Amit Kumar
    Bergquist, Timothy
    Li, Xiaochun
    Sharafeldin, Noha
    Topaloglu, Umit
    Su, Jing
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18672 - E18672
  • [26] Effectiveness of COVID-19 vaccines against severe outcomes in cancer patients: Real-world evidence from self-controlled risk interval and retrospective cohort studies
    Lee, Hui-Eon
    Jeong, Na-Young
    Park, Minah
    Lim, Eunsun
    Kim, Jeong Ah
    Won, Heehyun
    Kim, Chung-Jong
    Park, Sang Min
    Choi, Nam-Kyong
    [J]. JOURNAL OF INFECTION AND PUBLIC HEALTH, 2024, 17 (05) : 854 - 861
  • [27] THE IMPACT OF THE COVID-19 PANDEMIC ON PATIENTS WITH TYPE 2 DIABETES IN GREECE: RESULTS FROM A REAL-WORLD STUDY
    Dana, L.
    Poulia, K-A
    Doupis, J.
    Kotsopoulos, N.
    Yfantopoulos, I
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S481 - S482
  • [28] Outcomes of COVID-19 in patients with lymphomas participating in registered clinical trials: A real-world study from China in the Omicron outbreak era
    Sun, Peng
    Yang, Hang
    Zhao, Baitian
    Wang, Yu
    Nie, Man
    Huang, Kangming
    Li, Zhiming
    [J]. CANCER MEDICINE, 2023, 12 (23): : 21148 - 21158
  • [29] REAL-WORLD EFFECTIVENESS OF EARLY TREATMENTS FOR COVID-19: EVIDENCE FROM ADMINISTRATIVE CLAIMS DATA
    Bell, C.
    Lokhandwala, T.
    Gibbons, D.
    Patel, V
    Drysdale, M.
    Wang, J.
    Lloyd, E.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S24 - S24
  • [30] A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529)
    Mohammed, Hassen
    Pham-Tran, Dan Duy
    Yeoh, Zi Yi Michelle
    Wang, Bing
    McMillan, Mark
    Andraweera, Prabha H.
    Marshall, Helen S.
    [J]. VACCINES, 2023, 11 (02)